Lucerastat clinical trials
Lucerastat is named as an intervention in 2 current clinical trials in our UK, USA, Germany, Canada, France, Austria, Norway and Australia registers. 1 is recruiting patients now. All registered phases are Phase 3. The lead sponsor is Idorsia Pharmaceuticals Ltd. The most-studied condition is Fabry Disease. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Patient leaflets for Lucerastat
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Lucerastat
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease
NCT07778667 · Fabry Disease
|
Phase 3 | Recruiting | Idorsia Pharmaceuticals Ltd | UK, USA, Germany, Canada |
|
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease
NCT03737214 · Fabry Disease
|
Phase 3 | Active, closed | Idorsia Pharmaceuticals Ltd | France, Austria, Norway, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Lucerastat in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Lucerastat. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A multicenter, open-label, single-arm, baseline-controlled trial to assess the efficacy and safety of lucerastat in treatment-naïve/pseudo-naïve adult male participants with Fabry disease
2026-525207-27-00 · Nutritional and Metabolic Diseases
|
Phase 3 | Authorised | Idorsia Pharmaceuticals Ltd | Germany, France |
Conditions studied with Lucerastat
1 conditionSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Idorsia Pharmaceuticals Ltd | 2 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Lucerastat trials
How many clinical trials are testing Lucerastat?
2 current trials in our UK, USA, Germany, Canada, France, Austria, Norway and Australia registers name Lucerastat as a drug or biological intervention, as of the registry sync on 4 November 2026. Completed and withdrawn studies are not counted.
Are Lucerastat trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in UK, 1 with sites in USA, 1 with sites in Germany and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Lucerastat clinical trials?
The lead sponsor is Idorsia Pharmaceuticals Ltd. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Lucerastat works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Lucerastat works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Lucerastat (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 4 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.